Oxycodone for pain in fibromyalgia in adults.

BACKGROUND This review replaces part of an earlier review that evaluated oxycodone for both neuropathic pain and fibromyalgia, which has now been split into separate reviews for the two conditions. This review will consider pain in fibromyalgia only.Opioid drugs are commonly used to treat fibromyalgia, but they may not be beneficial for people with this condition. Most reviews have examined all opioids together. This review sought evidence specifically for oxycodone, at any dose, and by any route of administration. OBJECTIVES To assess the analgesic efficacy and adverse events of oxycodone for treating pain in fibromyalgia in adults. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to 25 July 2016. We also searched the reference lists of retrieved studies and reviews, and searched online clinical trial registries. SELECTION CRITERIA We planned to include randomised, double-blind trials of eight weeks' duration or longer, comparing oxycodone (alone or in fixed-dose combination with naloxone) with placebo or another active treatment. We did not include observational studies. DATA COLLECTION AND ANALYSIS The plan was for two independent review authors to extract data and assess trial quality and potential bias. Where pooled analysis was possible, we planned to use dichotomous data to calculate risk ratio and numbers needed to treat for one additional event, using standard methods. MAIN RESULTS No study satisfied the inclusion criteria. Effects of interventions were not assessed as there were no included studies. We have only very low quality evidence and are very uncertain about estimates of benefit and harm. AUTHORS' CONCLUSIONS There is no randomised trial evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia.

[1]  V. G. Lappi,et al.  High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews. , 2017, The Cochrane database of systematic reviews.

[2]  C. Sommer,et al.  WITHDRAWN: Anticonvulsants for fibromyalgia. , 2017, The Cochrane database of systematic reviews.

[3]  M. Bennett,et al.  Oxycodone for cancer-related pain. , 2017, The Cochrane database of systematic reviews.

[4]  J. Cappelleri,et al.  Evaluating Guideline‐recommended Pain Medication Use Among Patients with Newly Diagnosed Fibromyalgia , 2016, Pain practice : the official journal of World Institute of Pain.

[5]  R. Moore,et al.  Oxycodone for neuropathic pain in adults. , 2016, The Cochrane database of systematic reviews.

[6]  K Longley,et al.  EULAR revised recommendations for the management of fibromyalgia , 2016, Annals of the rheumatic diseases.

[7]  Daniel J Clauw,et al.  Opioid Use in Fibromyalgia: A Cautionary Tale. , 2016, Mayo Clinic proceedings.

[8]  P. Vergne-Salle,et al.  [Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain]. , 2016, Presse medicale.

[9]  E. Kalso,et al.  WHO analgesic ladder: a good concept gone astray , 2016, BMJ : British Medical Journal.

[10]  F. Wolfe,et al.  The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey , 2015, PloS one.

[11]  C. Maier,et al.  Erratum zu: Langzeittherapie mit Opioiden bei chronischem nicht-tumorbedingtem Schmerz , 2015, Der Schmerz.

[12]  W. Häuser,et al.  Langzeittherapie mit Opioiden bei chronischem nicht-tumorbedingtem Schmerz , 2015, Der Schmerz.

[13]  David A. Williams,et al.  Long-term Evaluation of Opioid Treatment in Fibromyalgia , 2015, The Clinical journal of pain.

[14]  T. Tölle,et al.  Long-term opioid use in non-cancer pain. , 2014, Deutsches Arzteblatt international.

[15]  P. Henningsen,et al.  Fibromyalgia syndrome: A somatoform disorder? , 2014, European journal of pain.

[16]  M. Janecki,et al.  Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release t , 2014, Current medical research and opinion.

[17]  F. Wolfe,et al.  What Is Fibromyalgia, How Is It Diagnosed, and What Does It Really Mean? , 2014, Arthritis care & research.

[18]  R. Moore,et al.  Oxycodone for neuropathic pain and fibromyalgia in adults. , 2014, The Cochrane database of systematic reviews.

[19]  Daniel J Clauw,et al.  Fibromyalgia: a clinical review. , 2014, JAMA.

[20]  P. Wiffen,et al.  Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. , 2014, The Cochrane database of systematic reviews.

[21]  S. Straube,et al.  The Costs and Consequences of Adequately Managed Chronic Non‐Cancer Pain and Chronic Neuropathic Pain , 2014, Pain practice : the official journal of World Institute of Pain.

[22]  K. Hamunen,et al.  Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. , 2013, The Cochrane database of systematic reviews.

[23]  G. Franklin,et al.  Opioids for chronic noncancer pain , 2013, Neurology.

[24]  A. Oaklander,et al.  Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia , 2013, PAIN®.

[25]  J. Langhorst,et al.  Posttraumatic stress disorder in fibromyalgia syndrome: Prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome , 2013, PAIN®.

[26]  L. Queiroz.  Worldwide Epidemiology of Fibromyalgia , 2013, Current Pain and Headache Reports.

[27]  D. Aldington,et al.  Amitriptyline for neuropathic pain and fibromyalgia in adults. , 2013, The Cochrane database of systematic reviews.

[28]  T. Tölle,et al.  Duloxetine use in chronic painful conditions – individual patient data responder analysis , 2013, European journal of pain.

[29]  Daniel Zeller,et al.  Small fibre pathology in patients with fibromyalgia syndrome. , 2013, Brain : a journal of neurology.

[30]  E. Kalso,et al.  Expect analgesic failure; pursue analgesic success , 2013, BMJ.

[31]  C. Benson,et al.  Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant pain. , 2013, Journal of opioid management.

[32]  F. Wolfe,et al.  Fibromyalgia Prevalence, Somatic Symptom Reporting, and the Dimensionality of Polysymptomatic Distress: Results From a Survey of the General Population , 2013, Arthritis care & research.

[33]  L. Arnold,et al.  The fibromyalgia family study: a genome-wide linkage scan study. , 2013, Arthritis and rheumatism.

[34]  S. Butler,et al.  Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. , 2013, The journal of pain : official journal of the American Pain Society.

[35]  E. Kalso,et al.  Does the pharmacology of oxycodone justify its increasing use as an analgesic? , 2013, Trends in pharmacological sciences.

[36]  S. Straube,et al.  Pain measures and cut‐offs – ‘no worse than mild pain’ as a simple, universal outcome , 2013, Anaesthesia.

[37]  M. Fitzcharles,et al.  Opioid Use in Fibromyalgia Is Associated with Negative Health Related Measures in a Prospective Cohort Study , 2013, Pain research and treatment.

[38]  M. Brennan.  The effect of opioid therapy on endocrine function. , 2013, The American journal of medicine.

[39]  Gordon H Guyatt,et al.  GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. , 2013, Journal of clinical epidemiology.

[40]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[41]  G. Úrrutia,et al.  Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. , 2013, The Cochrane database of systematic reviews.

[42]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[43]  F. Petzke,et al.  Ätiologie und Pathophysiologie des Fibromyalgiesyndroms , 2012, Der Schmerz.

[44]  F. Petzke,et al.  Das Fibromyalgiesyndrom , 2012, Der Schmerz.

[45]  F. Wolfe,et al.  The German fibromyalgia consumer reports – a cross-sectional survey , 2012, BMC Musculoskeletal Disorders.

[46]  C. Eccleston,et al.  Estimate at your peril: Imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses , 2012, PAIN.

[47]  Y. Lee,et al.  Candidate gene studies of fibromyalgia: a systematic review and meta-analysis , 2012, Rheumatology International.

[48]  Gordon H Guyatt,et al.  GRADE guidelines: 7. Rating the quality of evidence--inconsistency. , 2011, Journal of clinical epidemiology.

[49]  S. Straube,et al.  Interference with work in fibromyalgia - effect of treatment with pregabalin and relation to pain response , 2011, BMC musculoskeletal disorders.

[50]  H. McQuay,et al.  Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion , 2011, European journal of anaesthesiology.

[51]  F. Wolfe,et al.  Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia , 2011, The Journal of Rheumatology.

[52]  C. Sommer,et al.  Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta‐analysis , 2011, Arthritis care & research.

[53]  R. Baron,et al.  Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia , 2011, BMC neurology.

[54]  S. Straube,et al.  Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: Examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction , 2011, PAIN.

[55]  P. Wiffen,et al.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults. , 2011, The Cochrane database of systematic reviews.

[56]  P. Peloso,et al.  Numbers-needed-to-treat analyses – Do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials , 2010, PAIN®.

[57]  G. Fraser,et al.  The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. , 2010, The journal of pain : official journal of the American Pain Society.

[58]  C. Eccleston,et al.  “Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews , 2010, PAIN.

[59]  F. Petermann,et al.  [Influence of depression on fibromyalgia : A systematic review]. , 2010, Schmerz.

[60]  S. Straube,et al.  Pregabalin in fibromyalgia - responder analysis from individual patient data , 2010, BMC musculoskeletal disorders.

[61]  M. Lange,et al.  Einfluss von Depression auf das Fibromyalgiesyndrom , 2010, Der Schmerz.

[62]  A. Okamoto,et al.  Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain , 2010, Advances in therapy.

[63]  S. Straube,et al.  Chronic low back pain analgesic studies – A methodological minefield , 2010, PAIN.

[64]  O. Vasseljen,et al.  Association between physical exercise, body mass index, and risk of fibromyalgia: Longitudinal data from the Norwegian Nord‐Trøndelag Health Study , 2010, Arthritis care & research.

[65]  F. Wolfe,et al.  The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity , 2010, Arthritis care & research.

[66]  S. Straube,et al.  Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain , 2010, PAIN®.

[67]  D. Juurlink,et al.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone , 2009, Canadian Medical Association Journal.

[68]  L. Bradley.  Pathophysiology of fibromyalgia. , 2009, The American journal of medicine.

[69]  K. Olkkola,et al.  Oxycodone: new ‘old’ drug , 2009, Current opinion in anaesthesiology.

[70]  R. Moore,et al.  Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. , 2009, The Cochrane database of systematic reviews.

[71]  P. Wiffen,et al.  Pregabalin for acute and chronic pain in adults. , 2009, The Cochrane database of systematic reviews.

[72]  S. Derry,et al.  Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice , 2009, Annals of the rheumatic diseases.

[73]  S. Straube,et al.  Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. , 2008, British journal of clinical pharmacology.

[74]  R. Moore,et al.  Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials , 2008, BMC neurology.

[75]  M. Yunus,et al.  Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. , 2008, Seminars in arthritis and rheumatism.

[76]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[77]  E. Kalso.  How different is oxycodone from morphine? , 2007, PAIN.

[78]  Jessie Jones,et al.  An internet survey of 2,596 people with fibromyalgia , 2007, BMC musculoskeletal disorders.

[79]  O. Førre,et al.  Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. , 1999, The Journal of rheumatology.

[80]  D. Gavaghan,et al.  Size is everything – large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects , 1998, Pain.

[81]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[82]  A. Silman,et al.  The prevalence of chronic widespread pain in the general population. , 1993, The Journal of rheumatology.

[83]  E. Kalso,et al.  A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. , 1993, Journal of pain and symptom management.

[84]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[85]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[86]  A. Baranowski,et al.  Chronic widespread pain, including fibromyalgia: a pathway for care developed by the British Pain Society. , 2014, British journal of anaesthesia.

[87]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[88]  Jason G. Craggs,et al.  Patient-centered perspective on treatment outcomes in chronic pain. , 2010, Pain medicine.